Chern JW - Search Results

1

Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats.

Chen BM, Chan LY, Wang SM, Wu MF, Chern JW, Roffler SR. Chen BM, et al. Among authors: chern jw. Int J Cancer. 1997 Nov 4;73(3):392-402. doi: 10.1002/(sici)1097-0215(19971104)73:3<392::aid-ijc14>3.0.co;2-f. Int J Cancer. 1997. PMID: 9359487

2

Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.

Prijovich ZM, Chen BM, Leu YL, Chern JW, Roffler SR. Prijovich ZM, et al. Among authors: chern jw. Br J Cancer. 2002 May 20;86(10):1634-8. doi: 10.1038/sj.bjc.6600317. Br J Cancer. 2002. PMID: 12085215 Free PMC article.

3

Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).

Leu YL, Roffler SR, Chern JW. Leu YL, et al. Among authors: chern jw. J Med Chem. 1999 Sep 9;42(18):3623-8. doi: 10.1021/jm990124q. J Med Chem. 1999. PMID: 10479293

4

Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.

Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Cheng TL, et al. Among authors: chern jw. Bioconjug Chem. 2000 Mar-Apr;11(2):258-66. doi: 10.1021/bc990147j. Bioconjug Chem. 2000. PMID: 10725103

5

Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.

Wang SM, Chern JW, Yeh MY, Ng JC, Tung E, Roffler SR. Wang SM, et al. Among authors: chern jw. Cancer Res. 1992 Aug 15;52(16):4484-91. Cancer Res. 1992. PMID: 1643640

6

Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate.

Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E. Roffler SR, et al. Among authors: chern jw. Biochem Pharmacol. 1991 Oct 24;42(10):2062-5. doi: 10.1016/0006-2952(91)90612-9. Biochem Pharmacol. 1991. PMID: 1741786 No abstract available.

7

Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.

Cheng TL, Chen BM, Chan LY, Wu PY, Chern JW, Roffler SR. Cheng TL, et al. Among authors: chern jw. Cancer Immunol Immunother. 1997 Aug;44(6):305-15. doi: 10.1007/s002620050387. Cancer Immunol Immunother. 1997. PMID: 9298932 Free PMC article.

8

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.

Cheng TL, Wei SL, Chen BM, Chern JW, Wu MF, Liu PW, Roffler SR. Cheng TL, et al. Among authors: chern jw. Br J Cancer. 1999 Mar;79(9-10):1378-85. doi: 10.1038/sj.bjc.6690221. Br J Cancer. 1999. PMID: 10188879 Free PMC article.

9

Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.

Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. Cheng TL, et al. Among authors: chern jw. Bioconjug Chem. 1999 May-Jun;10(3):520-8. doi: 10.1021/bc980143z. Bioconjug Chem. 1999. PMID: 10346886

10

Characterization of an antineoplastic glucuronide prodrug.

Cheng TL, Chou WC, Chen BM, Chern JW, Roffler SR. Cheng TL, et al. Among authors: chern jw. Biochem Pharmacol. 1999 Jul 15;58(2):325-8. doi: 10.1016/s0006-2952(99)00072-6. Biochem Pharmacol. 1999. PMID: 10423174

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters